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Abstract 
Background: Chemokine ligand 13 (CXCL13) is believed to play a role in the recruitment of B cells in the central 
nervous system during neuroinflammation. Neurosyphilis is a group of clinical syndromes of the central nervous 
system caused by Treponema pallidum (T. pallidum) infection. The relationship between CXCL13 and neurosyphilis 
still needs further study. In our study, CSF and serum CXCL13 concentrations were detected among 40 neurosyphi‑
lis patients, 31 syphilis/non‑neurosyphilis patients, 26 non‑syphilis/other central nervous system diseases patients. 
Serum CXCL13 concentrations were detected in 49 healthy persons. All enrolled persons were HIV‑negative. Receiver 
operating characteristic (ROC) analysis was performed to determine the threshold value that could distinguish neuro‑
syphilis from syphilis.
Results: We found that the CSF CXCL13 concentrations and CXCL13 quotient (QCXCL13) were significantly increased 
in neurosyphilis patients compared to syphilis/non‑neurosyphilis (χ2 = 21.802, P < 0.001) and non‑syphilis patients 
(χ2 = 7.677, P = 0.002). ROC curve analyses revealed that CSF CXCL13 concentrations and QCXCL13 could serve as valu‑
able biomarkers for differentiating neurosyphilis from non‑neurosyphilis/syphilis.
Conclusions: The CSF CXCL13 and QCXCL13 could serve as valuable biomarkers for differentiating neurosyphilis from 
non‑neurosyphilis/syphilis in HIV‑negative patients.
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Background
Neurosyphilis is a group of clinical syndromes of the 
central nervous system caused by Treponema pallidum 
(T. pallidum) infection. Syphilitic infection of the cen-
tral nervous system can occur early or late in the course 
of the disease (Marra 2009). The clinical manifestations 
of neurosyphilis are protean, but the classification into 
asymptomatic, meningeal, meningovascular and paren-
chymatous disease is helpful and widely used (Friedrich 
et al. 2009). The diagnosis of neurosyphilis is based on a 
combination of clinical and laboratory findings. Accord-
ing to the guidelines of the United State Centers for 
Disease Control and Prevention, the cerebrospinal fluid 
(CSF) T. pallidum-specific antibody and non-treponemal 
CSF-venereal disease research laboratory (CSF-VDRL) 
tests can be used as two special markers to diagnose 
neurosyphilis (Workowski and Berman 2010). However, 
these tests are not sensitive or specific enough to detect 
all cases of neurosyphilis, and there is no perfect test to 
diagnose or exclude neurosyphilis. Because CSF-VDRL 
is an imperfect “gold standard” for the diagnosis of neu-
rosyphilis, laboratory diagnosis of neurosyphilis usually 
depends on various combinations of reactive serologic 
test results, such as CSF cell count and protein, or other 
markers of disease. Most of the other tests are both 
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insensitive and nonspecific and must be interpreted in 
relation to additional test results and clinical assessments.
In recent years, CSF CXCL13 concentrations have been 
suggested as a marker for the diagnosis of neurosyphilis 
in HIV-infected patients because they are independent 
of CSF pleocytosis and the markers of HIV (Marra et al. 
2010). CXCL13 is produced by antigen-presenting cells 
and is a selective chemoattractant for B cells and B-helper 
T cells in different neuroinflammatory diseases. CXCL13 
seems to be the major determinant of B cell recruitment 
to the central nervous system compartment in different 
neuroinflammatory diseases (Husson et al. 2002; Cadavid 
and Londono 2009). Elevated CXCL13 levels were found 
not only in the CSF of neurosyphilis patients with HIV 
infection but also in the CSF of patients with multiple 
sclerosis, acute Lyme neuroborreliosis, clinically isolated 
syndrome and other inflammatory neurological diseases 
(Kowarik et  al. 2012). Here, we assessed the regulatory 
response of CXCL13 in the CSF and serum of patients 
with neurosyphilis, syphilis and other central nervous 
system diseases, as well as healthy volunteers to explore 
the utility of CXCL13 concentrations in differentiating 




A retrospective study was performed in Zhongshan 
Hospital, Medical College of Xiamen, from Septem-
ber 2011 to March 2014. A total of 146 subjects were 
included in this study excluded three cases who were 
found to have syphilis 1  year, 2  years, 8  years ago by 
outpatient treatment. Forty patients were eligible for 
enrollment if they had clinical or serological evidence 
of neurosyphilis. Thirty-one patients with syphilis/non-
neurosyphilis (excluded from neurosyphilis) and 26 non-
syphilis patients with CSF abnormalities were enrolled in 
this study, while 49 healthy volunteers were used as con-
trols. The diagnoses of syphilis and neurosyphilis were 
determined as previously reported (Tong et  al. 2013a, 
2014). The 26 non-syphilis patients visited the hospital 
because of neurological symptoms and were ultimately 
diagnosed with central nervous system diseases by clini-
cal examination, including viral meningitis (8 patients), 
epileptic seizure (7 patients), spinal demyelination (3 
patients), Cryptococcus meningitis (2 patients), periph-
eral neuropathy (2 patients), Guillain-Barré syndrome 
(1 patient), multiple sclerosis (1 patient), motor neuron 
disease (1 patient), and encephalomyelitis (1 patient). All 
research subjects enrolled into our study were first-visit 
patients, none of them were treated for syphilis or neuro-
syphilis before the CSF collection. All participants were 
negative for HIV. Except for the healthy volunteers, all 
other participants underwent lumbar puncture accord-
ing to symptoms or signs. This study was approved by the 
Institutional Ethics Committee of the Medical College of 
Xiamen University and complied with national legislation 
and the Declaration of Helsinki guidelines.
Laboratory testing
CXCL13, rapid plasma reagin (RPR) and T. pallidum par-
ticle agglutination (TPPA) assay in serum and CSF for 
HIV-negative neurosyphilis were conducted at Zhong-
shan Hospital, Medical College of Xiamen University, 
from September 2011 to March 2014. All serological tests 
were performed using the same specimen, and the results 
of both tests were reported simultaneously. Serologic and 
CSF tests for syphilis were performed using RPR (Intec, 
Xiamen, China) and TPPA (Fujirebio, Tokyo, Japan) 
according to the manufacturer’s instructions and our pre-
vious studies (Lin et  al. 2010, 2011; Hu et  al. 2016; Wu 
et al. 2012). The concentrations of CXCL13 in the serum 
and CSF were measured using human CXCL13/BLC/
BCA-1 ELISA Kits (CUSABIO, Wuhan, China), accord-
ing to the manufacturer’s instructions. CSF protein, CSF 
and serum albumin and CSF white blood cell (WBC) 
examinations were performed according to the manu-
facturer’s instructions and our previous studies (Liu et al. 
2013a). HIV infection was excluded in all patients with 
electrochemiluminescence immunoassay (ECLIA) using 
HIV 1  +  2 antigens/antibodies (F. Hoffmann-La Roche 
Ltd., Basel, Switzerland). The albumin quotient (Qalb) was 
calculated using the following formulae: Qalb  =  (Albu-
minCSF/AlbuminSerum) × 10−3. All patients with impaired 
blood-CSF barriers (defined as albumin quotient [(Albu-
minCSF/AlbuminSerum)  ×  10−3  ≥  8.0] showed higher 
chemokine/cytokine levels in the CSF than patients 
with intact barriers (Kowarik et  al. 2012). The CXCL13 
quotient (QCXCL13) was calculated using the follow-
ing formulae: QCXCL13  =  [(CXCL13CSF/AlbuminCSF)/
(CXCL13Serum/AlbuminSerum)] (Kowarik et  al. 2012; Sti-
lund et al. 2014). The TPPA index was calculated accord-
ing to the following formula: CSF TPPA/(CSFalbumin  ×   
103/serumalbumin) (Mothapo et al. 2015).
Diagnostic criteria
Syphilis was diagnosed using serological data, personal/
medical history and clinical characteristics, according 
to US CDC (Workowski and Berman 2010) and ECDC 
guidelines (Janier et  al. 2014), as previously reported 
(Tong et al. 2014; Lin et al. 2010, 2011; Hu et al. 2016; Wu 
et al. 2012). The criteria for neurosyphilis diagnosis were 
described in a previous study (Tong et al. 2013a, 2013b; 
Mothapo et al. 2015; Liu et al. 2012).
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Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 17.0 (SPSS, Chicago, IL, USA). Normality of the 
distribution of continuous variables was tested by the 
Shapiro–Wilk test. Kruskal–Wallis H test was used 
for continuous variables with skewed distribution 
to determine differences among groups. The Neme-
nyi test was performed for multiple comparisons. The 
association among CXCL13 concentrations, clinical 
parameters, and CSF laboratory abnormalities was 
analyzed using the Spearman rank correlation test. 
The sensitivity, specificity, and area under the curve 
(AUC) for CSF CXCL13 concentrations, the QCXCL13, 
and serum CXCL13 concentrations were determined 
using receiver operator characteristic (ROC) analysis 
(Zajkowska et al. 2011). P < 0.05 was considered statis-
tically significant.
Results
Characteristics of the study subjects
The characteristics of the study participants were shown 
in Table  1. All of the enrolled subjects were nega-
tive for HIV. The concentrations of CXCL13 in the 
serum (χ2  =  72.115, P  <  0.001) and CSF (χ2  =  22.653, 
P  <  0.001) and QCXCL13 (χ2  =  15.110, P  =  0.001) were 
different among the neurosyphilis group, the syphilis/
non-neurosyphilis group, the non-syphilis group and 
the healthy volunteers. The serum CXCL13 level was 
significantly higher in the neurosyphilis and syphilis/
non-neurosyphilis groups than in the healthy volunteers 
(χ2 = 48.491, P < 0.001; χ2 = 17.170, P < 0.001). But there 
was no different in serum CXCL13 level either between 
neurosyphilis group and syphilis group, or neurosyphi-
lis group and non-neurosyphilis group. Furthermore, we 
have divided non-syphilis/other central nervous system 
Table 1 Characteristic of the study population
Characteristics of the study participants were shown in Table 1. Concentration of CXCL13 in serum , concentration of CXCL13 in CSF  and QCXCL13 were statistical 
significace and different among neurosyphilis group, syphilis/non-neurosyphilis group, non-syphilis group and healthy volunteers. The serum CXCL13 level was 
significantly higher in neurosyphilis and in syphilis/non-neurosyphilis as compared to healthy volunteers (x2 = 48.491, P < 0.001; x2 = 17.170, P < 0.001). The CSF 
concentration of CXCL13 was remarkably increased in patients with neurosyphilis as compared to the other two groups of syphilis/non-neurosyphilis (x2 = 21.802,  
P < 0.001) and non-syphilis (x2 = 7.677, P = 0.002). The QCXCL13 was higher in neurosyphilis as compared to syphilis/non-neurosyphilis (x2 = 12.352, P = 0.002) and as 
compared to non-syphilis (x2 = 9.335, P = 0.009). ND not detected
a Neurosyphilis versus healthy volunteers, P < 0.001; syphilis/non-neurosyphilis versus healthy volunteers, P = 0.008
b Neurosyphilis versus syphilis/non-neurosyphilis, P = 0.018; neurosyphilis versus non-syphilis/non CNS infection, P = 0.024; non-syphilis/other CNS infection versus 
non-syphilis/non CNS infection, P = 0.002
c Neurosyphilis versus healthy volunteers, P < 0.001; syphilis/non-neurosyphilis versus non-syphilis/other CNS infection, P = 0.022; syphilis/non-neurosyphilis 
versus healthy volunteers, P < 0.001; non-syphilis/other CNS infection versus healthy volunteers, P < 0.001; non-syphilis/non CNS infection versus healthy volunteers, 
P < 0.001
d Neurosyphilis versus syphilis/non-neurosyphilis, P < 0.001; neurosyphilis versus non-syphilis/non CNS infection, P = 0.009
e Neurosyphilis versus syphilis/non-neurosyphilis, P = 0.001; neurosyphilis versus non-syphilis/non CNS infection, P = 0.003
f Data was compared to different groups, the difference was statistically significant







Other CNS infection 
(n = 11)
Non CNS infection 
(n = 15)
n (%) n (%) n (%) n (%) n (%)
Male sex 30 (75.0) 18 (58.1) 6 (54.5) 6 (40) 28 (57.1) 0.158
Serum RPR ≥ 1:32 20 (50.0) 4 (12.9) 0 0 0
Reactive CSF RPR 23 (57.5) 0 0 0 0
P50 (P25–P75) P50 (P25–P75) P50 (P25–P75) P50 (P25–P75) P50 (P25–P75)
Agea (years) 54 (46–58) 49 (39–59) 41 (29–52) 50 (24–70) 34 (28–47) <0.001f
CSF WBCb 
(10 × 106/L)
25 (8–126) 7 (3–14) 53 (7–82) 5 (2–13) ND 0.001f
CSF Protein 
(500 mg/L)
461.3 (351.2–676.9) 386.6 (323.6–523.9) 853.3 (266.0–1499.1) 478.5 (344.2–587.2) ND 0.141
albumin quotient 6.0 (4.2–8.9) 5.3 (3.4–7.2) 9.0 (5.2–17.8) 8.8 (3.9–18.1) ND 0.058
Serum CXCL13c (pg/
mL)
140.3 (82.5–200.5) 82.5 (55.0–136.7) 170.2 (158.4–188.7) 118.7 (96.0–188.7) 23.4 (15.0–37.4) <0.001f
CSF CXCL13d (pg/mL)f 10.1 (5.2–20.8) 0.4 (0–3.9) 5.4 (1.4–14.8) 0.1 (0–8.8) ND <0.001f
QeCXCL13 9.3 (4.6–32.0) 0.6 (0–13.0) 3.9 (0.5–8.7) 0.1 (0–4.8) ND <0.001
f
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diseases into 11 patients with viral or cryptococcal infec-
tion diseases and 15 patients with noninflammatory neu-
rological disorders. The serum CXCL13, CSF CXCL13 
and QCXCL13 were analyzed again. The results showed 
that serum CXCL13 concentrations had no value to dif-
ferentiate between neurosyphilis and other neurologic 
viral and cryptococcal infection diseases or other non-
inflammatory neurological disorders (Fig.  1a). The CSF 
concentrations of CXCL13 were remarkably increased 
in patients with neurosyphilis compared to patients with 
syphilis/non-neurosyphilis (χ2 =  21.802, P  <  0.001) and 
patients with non-syphilis/non central nervous system 
Fig. 1 Scatterplot of serum CXCL13 concentrations (a), CSF CXCL13 concentrations (b) and QCXCL13 (c) in different groups which was used a 
logarithmic scale for the Y‑axis. a The concentrations of CXCL13 in serum were statistically different among the five groups. The concentrations in 
the healthy group were statistically lower than the other four groups (P < 0.001). The concentrations in syphilis/non‑neurosyphilis were statistically 
lower than non‑syphilis/other CNS infection group (P = 0.022). The concentrations in neurosyphilis group were higher than syphilis/non‑neuro‑
syphilis group, but there was no statistical difference (P = 0.084). b The concentrations of CXCL13 in CSF were statistically different among the four 
groups. The concentrations in the neurosyphilis group were statistically higher than the syphilis/non‑neurosyphilis (P < 0.001), and non‑syphilis/non 
CNS infection group (P = 0.009). c The QCXCL13 in CSF were statistically different among the four groups. The QCXCL13 in the neurosyphilis group were 
statistically higher than the syphilis/non‑neurosyphilis (P = 0.001), and non‑syphilis/non CNS infection group (P = 0.003)
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(CNS) infection group (χ2 =  9.340, P =  0.009, Fig.  1b). 
The QCXCL13 was higher in the neurosyphilis group than 
the syphilis/non-neurosyphilis (χ2  =  12.352, P  =  0.002, 
Fig. 1c) and non-syphilis groups (χ2 = 11.528, P = 0.003, 
Fig. 1c). 
Furthermore, we explored the differences in the con-
centrations of CXCL13 in the serum and CSF and the 
QCXCL13 among patients with different types of neuro-
syphilis. Based on its clinical manifestations, neuro-
syphilis can be divided into asymptomatic neurosyphilis, 
syphilitic meningitis, meningovascular neurosyphilis, 
general paresis, and tabes dorsalis. Of the 40 patients 
with neurosyphilis in the present study, 16 (40  %) had 
syphilitic meningitis, which accounted for the highest 
proportion of neurosyphilis, followed by general pare-
sis (10, 25 %), meningo vascular neurosyphilis (6, 15 %), 
asymptomatic neurosyphilis (6, 15  %), and tabes dorsa-
lis (2, 5 %). There was no significant difference in serum 
CXCL13 and CSF CXCL13 concentrations and the 
QCXCL13 among patients with different types of neuro-
syphilis (Table 2).
CXCL13 as a potential differentiation marker 
of neurosyphilis and non-neurosyphilis/syphilis
The diagnostic potential and discriminatory accuracy 
of CSF CXCL13 concentrations and the QCXCL13 were 
evaluated by ROC curve analysis and the corresponding 
AUC values (Fig. 2). ROC analysis revealed that the CSF 
CXCL13 levels were robust in discriminating patients 
with neurosyphilis and non-neurosyphilis/syphilis, with 
an AUC value of 0.831 (95 % CI 0.724–0.938, P = 0.000). 
The highest accuracy was noted at a cut-off expression 
value of 4.871 pg/mL, where the sensitivity and specific-
ity were 80.0 and 81.4 %, respectively. In addition, ROC 
curve analysis revealed that the QCXCL13 can also serve 
as a valuable biomarker for differentiating neurosyphilis 
from non-neurosyphilis/syphilis, with an AUC of 0.758 
(95 % CI 0.620–0.895, P = 0.001). At a cut-off value less 
than 2.408 for QCXCL13, the sensitivity and specificity 
were 87.5 and 69.2 %, respectively.
Correlations between CXCL13 and TPPA index/WBC in CSF
There was no correlation between TPPA index and CSF 
CXCL13 (r = 0.087, P = 0.593), and QCXCL13 (r = 0.054, 
P = 0.752). It was same to CXCL13 and leucocyte count 
(r = 0.211, P = 0.191).
Discussion
The diagnosis of neurosyphilis is still dependent on clini-
cal and laboratory parameters that are not sufficiently 
sensitive. Scientists have made an effort to identify 
laboratory tests with high sensitivity and specificity for 
diagnosing neurosyphilis. In recent years, Marra et  al. 
reported that CSF CXCL13 concentration may be par-
ticularly useful for diagnosing neurosyphilis in HIV-
infected patients. Are these concentrations also useful in 
HIV-negative and with neurosyphilis patients? We retro-
spectively reviewed 97 inpatients from Zhongshan Hos-
pital, Medical College of Xiamen University, China. Forty 
were HIV-negative and with neurosyphilis. In this study, 
the serum CXCL13 level was significantly higher in neu-
rosyphilis and in syphilis/non-neurosyphilis patients 
Fig. 2 Receiver operating characteristics (ROC) curve analysis using 
CSF CXCL13 and QCXCL13 for discriminating neurosyphilis from non‑
neurosyphilis/syphilis. a CSF CXCL13 yielded an AUC (the areas under 
the ROC curve) of 0.831 (95 % CI 0.724–0.938, P = 0.000) with 80.0 % 
sensitivity and 81.4 % specificity in discriminating neurosyphilis from 
non‑neurosyphilis/syphilis. b QCXCL13 yielded AUC of 0.758 (95 % CI 
0.620–0.895, P = 0.001) with 87.5 % sensitivity and 69.2 % specificity 
in discriminating neurosyphilis from non‑neurosyphilis/syphilis
Table 2 Serum and CSF CXCL13 concentrations in patients with different type of neurosyphilis
Kruskal–Wallis H test was used to determine differences among different types of neurosyphilis
Type of NS No % Serum CXCL13 (pg/mL) CSF CXCL13 (pg/mL) CXCL13 index
Asymptomatic NS 15 % (6/40) 99.625 ± 51.757 10.458 ± 10.412 18.207 ± 14.652
Syphilitic meningitis 40 % (16/40) 166.034 ± 103.049 12.108 ± 8.129 71.767 ± 234.272
Meningovascular syphilis 15 % (6/40) 118.4201 ± 64.751 37.526 ± 70.852 62.473 ± 99.766
General paresis 25 % (10/40) 170.565 ± 93.286 33.405 ± 47.882 37.426 ± 55.628
Tabes dorsalis 5 % (2/40) 102.769 ± 81.190 17.804 ± 22.632 34.548 ± 42.221
χ2 value 5.226 0.334 3.190
P value 0.265 0.987 0.527
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than in healthy volunteers (χ2  =  48.491, P  <  0.001; 
χ2 = 17.170, P < 0.001). However, there was no difference 
in serum CXCL13 levels among the neurosyphilis, syphi-
lis/non-neurosyphilis, and non-syphilis patients. We 
have further divided non-syphilis/other central nerv-
ous system diseases into infectious group and without 
infectious group. The serum CXCL13, CSF CXCL13 and 
QCXCL13 were analyzed again. The results showed that 
serum CXCL-13 could not differentiate the neurosyphi-
lis from other neurologic viral and cryptococcal infec-
tion diseases. Therefore, serum CXCL13 levels can’ t be 
used to support the diagnosis of neurosyphilis in HIV-
negative patients.
However, we demonstrated significantly elevated levels 
of CSF CXCL13 in HIV-negative neurosyphilis patients 
compared to the other groups, which were similar to the 
observations conducted by Mothapo et al. (Mothapo et al. 
2015). This article analyzed 103 syphilis patients with 47 
non-HIV-infected patients. However, only six patients 
with neurosyphilis were also HIV-negative in their study, 
a number that was too small. In our study, we enlarged the 
study population. Was an excess of CXCL13 produced by 
monocytes in the CSF or the blood? Our study found that 
the mean albumin quotient was equal to or greater than 
8.0 in neurosyphilis patients and non-syphilis neurological 
patients, which suggested that the blood brain barrier was 
damaged in these patients (Kowarik et  al. 2012). Blood-
CSF barrier dysfunction may lead T. pallidum invasion of 
the central nervous system, stimulating a local immune 
reaction and resulting in intrathecal synthesis of CXCL13 
(Hytonen et  al. 2014). Therefore, we investigated the 
QCXCL13 to estimate the intrathecal synthesis of CXCL13, 
excluding the influence of blood CXCL13 contamina-
tion. The results showed that the QCXCL13 in neurosyphilis 
patients was significantly higher than in syphilis/non-neu-
rosyphilis patients, suggesting that intrathecal synthesis of 
CXCL13 did occur in HIV-negative neurosyphilis patients.
ROC analysis revealed that the CSF CXCL13 levels 
were robust in discriminating patients with neurosyphi-
lis and non-neurosyphilis/syphilis, with an AUC of 0.831 
(95 % CI 0.724–0.938, P = 0.000). The highest accuracy 
was at a cut-off value of 4.871  pg/mL, where the sensi-
tivity and specificity were 80.0 and 81.4  %, respectively. 
The sensitivity and specificity in our study were higher 
than those in previous research (Marra et al. 2010). The 
proposed cut-off for abnormal CSF CXCL13 was low in 
comparison to similar studies regarding neuroborrelio-
sis. Elevated CSF CXCL13 concentration has been shown 
to be a good marker for active Lyme neuroborreliosis 
(Hytonen et al. 2014; Bremell et al. 2013; Moniuszko et al. 
2014; Wutte et al. 2014). The major findings of Ruppre-
cht et al. study was that high levels of CXCL13 could be 
found in the CSF of patients with the two most common 
spirochetal CNS diseases, NB and NS, but the elevated 
CSF CXCL13 levels in patients with neurosyphilis were 
lower than in patients with neuroborreliosis (Ruppre-
cht et  al. 2007). There is substantial genotypic variation 
among Borrelia burgdorferi stains (Petzke and Schwartz 
2015). The number of outer membrane proteins of Borre-
lia burgdorferi were more than T. pallidum. These may be 
the reason why the elevated CSF CXCL13 levels in neu-
rosyphilis patients were lower than in neuroborreliosis 
patients. CXCL-13 positive results could be detected in 
patients with other neurological infectious diseases based 
on the cut-off for abnormal CXCL-13 in CSF (4.871 pg/
ml). The neurological infectious diseases can be differen-
tially diagnosed by microbiological and parasitological 
test, and brain imaging etc. However, T. pallidum causes 
syphilis and can only be cultured in vivo, and it is hard to 
detected in CNS directly. NS has various clinical mani-
festations, laboratory findings, magnetic resonance imag-
ing and electroencephalogram findings, thus establishing 
the diagnosis is often difficult. There are few clinical cri-
teria and no national guidelines available (gold standard) 
for NS diagnosis (Liu et  al. 2013b). We found that CSF 
CXCL13 could also serve as a valuable supplementary 
biomarker for differentiating neurosyphilis from non-
neurosyphilis/syphilis with HIV-negative patients. In 
Marra’s paper, she indicated that CSF CXCL13 ≥ 10 pg/
mL could be used as a diagnostic indicators for symp-
tomatic neurosyphilis characterized by high sensitivity 
(90 %) but low specificity (37 %) (Marra et al. 2010). The 
cut-off value for CSF CXCL13 in our study was lower 
than that in the study by Marra. This was mainly due 
to the different study population in the Marras’ article 
which comprised HIV-positive neurosyphilis patients. 
As we know, HIV can promote development of T. palli-
dum infection. Perhaps co-infection of T. pallidum and 
HIV promote the production of more CSF CXCL13 than 
T. pallidum infection alone. In Khutso’s study, authors 
used the positive CSF RPR as the gold standard for diag-
nosing neurosyphilis, on that criterion, only 6 out of 47 
HIV-negative patients were neurosyphilis and included 
in HIV seronegative group. That is to say, the study sub-
jects of HIV-negative neurosyphilis patients were too 
small to represent the CSF CXCL13 results of neuro-
syphilis patients (Mothapo et al. 2015). The elevated CSF 
CXCL13 levels were also indicated in Hu et  al. report 
(2016) due to HIV and T. pallidum co-infection. In Hu 
et  al.’s study, only 4 patients were diagnosed with neu-
rosyphilis due to a positive CSF-VDRL (Hu et al. 2016). 
The number of neurosyphilis cases were also too small 
to reflect the real situation of CSF CXCL13 in the neu-
rosyphilis. However, in our study, we mainly focused on 
HIV-negative patients, not only because the less popula-
tion of co-infection of HIV and T. pallidum but also to 
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rule out the impact of the HIV virus. The HIV-negative 
population in our research is the main difference from 
previous study. In addition, some scholars have indi-
cated that the T. pallidum in different area was various 
in genotypes, so as to lead to differing in pathogenicity. 
For example, Wu et  al. reported that subtype 14f/f (18 
isolates) was the most common isolate in Taiwan, fol-
lowed by 14 f/c (3), 14 b/c (3), and 14 k/f (Wu et al. 2012). 
Florindo et al. indicated that the predominant subtype in 
European countries, subtype was 14a, followed by 14d 
and 14f, which was different from the genotype in Taiwan 
(Florindo et al. 2008). This geographic distribution of dif-
ferent genotype of T. pallidum may also partly explain 
why our results are lower than those of other reports. 
Our further analyses revealed that the QCXCL13 could also 
serve as a valuable biomarker for differentiating neuro-
syphilis from non-neurosyphilis/syphilis, with an AUC 
of 0.758 (95 % CI 0.620–0.895, P = 0.001). At the cut-off 
value less than 2.408 for the QCXCL13, the sensitivity and 
the specificity were 87.5 and 69.2  %, respectively. The 
study results showed that the QCXCL13 was more sensi-
tive (87.5 vs. 80.0 %) than CSF CXCL13. Therefore, CSF 
CXCL13 and QCXCL13 may be useful as markers for the 
diagnosis of neurosyphilis in HIV-negative patients.
In our study, the positive rate for the CSF RPR test was 
55  %, similar to the literature reports of 50  % (Busl and 
Bleck 2013). According to the 2008 European Guidelines 
on the Management of Syphilis, a TPPA index >70 is most 
reliable in supporting the diagnosis of neurosyphilis, simi-
lar to the T. pallidum hemagglutination index (Mothapo 
et al. 2015). We had reported that the TPPA index signifi-
cantly correlated with CSF WBCs. Thus, we investigated 
the correlation between CXCL13 levels and the TPPA 
index, as well as CXCL13 levels and CSF WBCs. The 
result showed that there was no correlation between CSF 
CXCL13 and CSF TPPA index/CSF WBCs. Therefore, our 
results suggest that intrathecal T. pallidum antibody pro-
duction will not correlate with the induction of CXCL13. 
Because of the poor sensitivity of the CSF RPR and the 
low specificity of the CSF TPPA, CSF CXCL13 concen-
trations may serve as a supplementary biomarker of 
neurosyphilis. Does the CXCL13 concentration relate to 
the progression of neurosyphilis? To investigate whether 
there are particular types of neurosyphilis that are asso-
ciated with CXCL13 production, we further analyzed the 
serum and CSF concentrations of CXCL13 in different 
types of neurosyphilis. There were no significant differ-
ences among them. This suggests that the central nervous 
system damage caused by various types of neurosyphilis 
has similar effects on the central nervous system.
To the best of our knowledge, this is the first article to 
analyze the relationship between HIV-negative neurosyph-
ilis and the QCXCL13, and is the first large sample analysis 
to describe the relationship between HIV-negative neu-
rosyphilis and CXCL13 levels. Several limitations of our 
study should be acknowledged, such as the potential mis-
classification of different types of neurosyphilis patients 
with a prior history of syphilis due to inadequate medical 
records or hospital public health registries. Additionally, 
because healthy persons did not undergo an immedi-
ate lumbar puncture, we could not compare CSF results 
between the neurosyphilis group and the healthy controls.
In conclusion, when infection of T. pallidum occurs, 
CSF CXCL13 levels and QCXCL13 may be potential mark-
ers for the diagnosis of neurosyphilis, as demonstrated 
by the elevated CSF CXCL13 levels in patients with 
suspected neurosyphilis. CSF CXCL13 levels and the 
QCXCL13 are novel important promising biomarkers in 
differentiating neurosyphilis patients from non-neuro-
syphilis/syphilis patients without HIV infection.
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